

Oncology Today with Dr Neil Love: Managing Transplant-Ineligible Newly Diagnosed Multiple Myeloma**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- In the Phase III TOURMALINE-MM3 and -MM4 trials evaluating a maintenance therapy for transplant-eligible and -ineligible patients with newly diagnosed multiple myeloma (MM), which of the following maintenance therapies was compared with placebo?**
 - Bortezomib
 - Lenalidomide
 - Ixazomib**
- Which of the following findings have been reported from the Phase III ENDURANCE trial evaluating VRd vs KRd induction in patients with newly diagnosed MM?**
 - Significantly improved progression-free survival with VRd
 - Significantly improved progression-free survival with KRd
 - Significantly increased rate of cardiac, pulmonary, and renal adverse events with KRd**
 - Significantly increased rate of cardiac, pulmonary, and renal adverse events with VRd
- Comprehensive geriatric assessments to help clinicians assess patient frailty measure which of the following?**
 - Cognitive functioning only
 - Comorbidities, medications, and socioeconomic factors only
 - Physical performance measures only
 - All of the above**
- In the Phase III trial evaluating lenalidomide plus dexamethasone with or without ixazomib in patients with newly diagnosed transplant-ineligible MM, which of the following results have been reported?**
 - The addition of ixazomib did not improve progression-free survival
 - The objective response rate was not improved with the addition of ixazomib
 - The rate of measurable residual disease (MRD) negativity was improved with the addition of ixazomib**